<small>A histopathological review preliminary of 429 patients diagnosed
with tumours of the uterine corpus (TUC) cancer between 1984- 2010 in
the Vigo University Hospital Complex (Spain) were evaluated
prospectively for over 5 years. Of these 403 (93.9%) were epithelial
tumours: 355 (82.7%) were adenocarcinomas of the endometrioid type, 5
(1.1%) mucinous adenocarcinoma, 10 (2.3%) serous adenocarcinoma, 17
(3.9%) clear cell carcinomas, 11 (2.5%) mixed adenocarcinoma, 4 (0.9%)
undifferentiated carcinomas and 1 (0.2%) squamous cell carcinomas. A
total 20 (4, 6%) were mesenchymal tumours: 4 (0.9%) endometrial stromal
sarcoma, 7 (1.6%) Leiomyosarcoma, 9 (2%) Mixed endometrial stromal and
smooth muscle tumour. A total 1 (0.2%) were mixed epithelial and
mesenchymal tumours: (0.2%) Adenosarcoma 1. And 5 (1.1%) were Metastases
from extragenital primary tumour (3 carcinomas of the breast, 1 stomach
and 1 colon). The mean age at diagnosis from total series were 65, 4
years (range 28-101 years). Age was clearly related to histologic type:
Endometrial stromal sarcoma 46.0 years, Leiomyosarcomas 57.1 years,
Adenocarcinomas of the endometrioid type 65.4 years, Clear cell
carcinomas 70.1 years and mixed endometrial stromal and smooth muscle
tumours 71.2 years. Five-year disease-free survival rates for the entire
group were: Endometrial stromal sarcoma 50%, Leiomyosarcomas 28.6%,
Adenocarcinomas of the endometrioid type 83.7%, Clear cell carcinomas
64.7% and mixed endometrial stromal and smooth muscle tumours 44.4%. The
5-year disease-free survival rates of patients with Adenocarcinomas of
the endometrioid type tumors were 91.4% for grade 1 tumors, 77.5% for
grade 2, and 72.7% for grade 3.</small
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.